Corline Biomedical AB
The answer first
Does Corline Biomedical beat the market?
No, Corline Biomedical has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 3% of Nordic stocks
- Quality28
- Value7
- Trend16
No. 184 of 195 in healthcare
Max for seven days
Follow Corline Biomedical with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Corline Biomedical
Your first answer is free, no account needed.
Do you own Corline Biomedical, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Corline Biomedical and a few more. Free, no card.
Super Stock+45.9%In short
- Corline Biomedical has fallen 20.3% over the past year, including dividends.
- Overall, Corline Biomedical ranks better than 3% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 65.9%. The price is 47.7% below its peak now.
What do analysts think of Corline Biomedical?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 3% of Nordic stocks.
No. 184 of 195 in healthcare
Low Weaker accounts than most: low profitability, high debt or uneven results.
No. 160 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.00
- Asset turnoverSales divided by everything the company owns0.11
- Return on equityProfit divided by equity−12.4%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 149 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50
- P/BPrice divided by equity3.6
- P/SPrice divided by sales28.8
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 135 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−20.3%
- 6 months−21.2%
- 9 months−4.0%
- 12 months−20.3%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Corline Biomedical
One fund we follow owns Corline Biomedical. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About Corline Biomedical
Corline Biomedical AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 14 employees.
Corline Biomedical AB (publ) develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a naturally occurring biomolecule heaparin, which is routinely used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting.


See the full analysis of Corline Biomedical.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card